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Urodynamics is well established in functional urological assessment, but its 
contribution is often questioned. Uncertainty stems from modern-day focus on 
evidence based medicine, where well-constructed research is essential justification 
for an intervention. A recent Cochrane analysis found that urodynamics changes 
clinical decision making, but there was no evidence to demonstrate whether this led 
to reduced symptoms of voiding dysfunction after treatment [1]. Where such 
evidence is lacking, other factors come into play, such as opinion, service delivery, 
cost and convenience. In the European Association of Urology Guidelines on Non-
neurogenic Male lower urinary tract symptoms (LUTS) [2], the research evaluated in 
urodynamics was only rated as Level of Evidence C. Consequently, the Delphi 
process was used to derive consensus based on expert opinion. Only partial 
agreement was gained and there was even discrepancy between age groups (that 
pressure flow studies “may” be performed in men aged over 80 years, and “should” 
be if aged under 50 years). 
Assessment of men referred with LUTS aims to exclude “red flag” diagnoses, avoid 
complications of disease or therapy, focus on bothersome symptoms, and use 
interventional therapy selectively. Routinely, all men with persisting bothersome 
voiding LUTS are expected to undergo history and examination, with symptom 
scores, urinalysis, flow rate testing and post void residual measurement [2]. 
Multichannel urodynamics in modern care pathways is for those men who remain 
bothered by voiding LUTS despite initial treatment, and therefore may be under 
consideration for interventional care. The aim is to decide whether an individual 
would realistically benefit from relief of bladder outlet obstruction (BOO), and 
whether there are risk factors for adverse outcome, such as detrusor underactivity 
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during voiding (DUA), or detrusor overactivity (DO) during storage. However, there is 
a dichotomised situation;  
 Advocates for routine use of urodynamics suggest surgery should only be 
undertaken if BOO is present, arguing that any man undergoing surgery who 
does not have BOO cannot benefit symptomatically, and will be at risk of 
adverse effects of intervention (e.g. retrograde ejaculation induced by 
transurethral resection of the prostate). 
 Advocates for restricted (selective or non-) use of urodynamics point to 
perceived unpleasant experience, the lack of evidence of better outcomes, 
and the associated costs. A survey found only 34% of men having surgery 
underwent prior urodynamics testing [3].  
Routine use of urodynamics should ensure suitable indications for surgery, but 
imposes cost to the health economy and patients during assessment. Restricted use 
of urodynamics generally means that BOO is presumed, though DUA may actually 
be causative, so a higher proportion of men with voiding LUTS will undergo surgery; 
additional costs consequently fall later in the care pathway, with a higher demand for 
surgery, and potential life-long impact on the minority of men who underwent surgery 
that turned out to be “unnecessary”, or suffered complications. In either case, clinical 
outcomes and health economic costs are substantial issues.  
The UK National Health Institute of Health Research (NIHR) reviewing the care of 
Male LUTS [4] recognised the need for evidence-based understanding of 
urodynamics. In 2014, they funded the UPSTREAM study (NIHR project number 
12/140/01) [5]. UPSTREAM is a two-arm randomised controlled trial set in 26 
Hospitals. Men (n=800, ≥18 years) seeking further treatment for their bothersome 
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LUTS for whom surgeons would consider offering surgery, are randomised to either 
an assessment pathway including invasive urodynamics (plus routine non-invasive 
tests (intervention)), or only with routine non-invasive tests (control). The study aims 
to determine whether the control arm is non-inferior in terms of symptom outcome 
(International Prostate Symptom Score) at 18-months after randomisation. It will also 
establish whether inclusion of invasive urodynamics reduces rates of bladder outlet 
surgery. Full details are published elsewhere [5]. 
Non-inferiority of symptom outcome was chosen, rather than looking whether 
urodynamics achieves symptom superiority, due to several uncertainties, including; 
1. The lower surgery rate anticipated in the urodynamic group means a larger 
proportion of men would effectively get minimal additional treatment. 
2. Quality of urodynamic testing is a confounding variable, so that the urodynamics 
pathway would be affected adversely where the test is not done to necessary 
standards. Central reading of records against International Continence Society 
standards [6] is undertaken to gauge the potential impact of service quality.   
3. Does surgery actually achieve relief of BOO? Flow tests 4-months after surgery 
are used to gauge likelihood that BOO was relieved (repeat urodynamic testing was 
not considered feasible). If maximum flow rate is actually not improved, it would 
indicate quality of surgery is a confounding variable, as differing surgery rates 
between the pathways is anticipated.  
4. Treatment is not randomised nor stipulated by the trial, but selected by the patient 
on discussion with the urologist. Accordingly, patients may choose not to receive the 
treatment suggested by the investigations, and the surgeon may also follow 
individual practice preference.  
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 5. Treatment effects are incompletely understood. For example, it is not clear 
whether men with DUA gain a sustained improvement as a result of surgery to 
relieve BOO using modern methods. Outcomes for men undergoing management of 
voiding LUTS who also have storage LUTS is hard to anticipate, and particularly for 
nocturia [7].  
The strongly-held views urologists sometimes express towards urodynamics do not 
preclude equipoise in randomising men between care pathways which include or 
exclude urodynamic testing. In particular, the range of tests in the non-urodynamic 
pathway enables clinicians to surmise BOO correctly in the majority of cases. For 
men with storage LUTS, it is not clear on current evidence whether the symptoms 
are the critical factor for adverse treatment outcome, or the presence of DO. After 
UPSTREAM reports in 2018, there will be a strong evidence basis for the various 
tests conventionally used in the assessment of male LUTS in terms of therapeutic 
choice and outcome, and insight into patient perceptions of the diagnostic pathway. 
UPSTREAM will provide high quality randomised scientific evidence to understand 
the actual importance, or lack thereof, of the diagnostic observations made in 
urodynamic testing. The study will be greatly beneficial to patients, carers and health 
economies, in providing a solid basis for guiding diagnostic testing and the use of 
urodynamics in male LUTS.      
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Take home message; (separate file): 
Insufficient evidence exists regarding the role of invasive urodynamics in routine 
practice in the clinical assessment of male LUTS. UPSTREAM, a multicentre 
randomised trial, will inform patients, clinicians and policy makes about whether 
urodynamics should be more widely used for such patients. 
 
